Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 42: 1645-1653, 1996;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rainey, P. M.
Right arrow Articles by Roberts, W. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rainey, P. M.
Right arrow Articles by Roberts, W. L.

Clinical Chemistry, Vol 42, 1645-1653, Copyright © 1996 by American Association for Clinical Chemistry

Metabolite and matrix interference in phenytoin immunoassays

PM Rainey, KE Rogers and WL Roberts
Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT 06504, USA. petrie.rainey@yale.edu

The major phenytoin metabolite, 5-(p-hydroxyphenyl)-5-phenylhydantoin glucuronide (HPPG), was primarily responsible for the positive bias noted when uremic specimens were assayed with the Abbott TDx Free Phenytoin fluorescence polarization immunoassay. The amount of bias depended on both HPPG and phenytoin concentration, increasing with increases in either concentration. The new Abbott TDx II assays for phenytoin and free phenytoin exhibited no significant cross-reactivity with HPPG and no bias in clinical specimens from uremic patients. Both assays correlated well with Emit-based assays (r >0.98), had CVs of <3.5%, and had minimum detection limits of <0.1 mg/L. Calibration curves were stable for at least 6 weeks. All of the TDx assays cross- reacted with another metabolite, 5-(p-hydroxyphenyl)-5-phenylhydantoin (HPPH), but expected HPPH concentrations are too low to cause a clinically significant bias. The Emit-based phenytoin assay exhibited a significant matrix effect when calibrators were prepared in defibrinated plasma processed to resemble serum.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
M. Oellerich and V. W. Armstrong
Prodrug Metabolites: Implications for Therapeutic Drug Monitoring
Clin. Chem., May 1, 2001; 47(5): 805 - 806.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
W. L. Roberts, B. K. De, J. P. Coleman, and T. M. Annesley
Falsely Increased Immunoassay Measurements of Total and Unbound Phenytoin in Critically Ill Uremic Patients Receiving Fosphenytoin
Clin. Chem., June 1, 1999; 45(6): 829 - 837.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
A. R. Kugler, T. M. Annesley, G. D. Nordblom, J. R. Koup, and S. C. Olson
Cross-reactivity of fosphenytoin in two human plasma phenytoin immunoassays
Clin. Chem., July 1, 1998; 44(7): 1474 - 1480.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
P. Datta
Oxaprozin and 5-(p-Hydroxyphenyl)- 5-phenylhydantoin Interference in Phenytoin Immunoassays
Clin. Chem., August 1, 1997; 43(8): 1468 - 1469.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the American Association for Clinical Chemistry.